Credit rating agency, CARE has assigned AA+ rating to Ranbaxy Laboratories’ long-term proposed Non Convertible Debentures (NCD) worth Rs 500 crore.
The company has received the said rating on the back of its dominant position in the domestic pharmaceutical market coupled with its established presence in the global market, which is further expected to strengthen, given its strong pipeline of Abbreviated New Drug Applications (ANDA), including First-to-file (FTF) applications.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1938.95 |
| Dr. Reddys Labs. | 1246.95 |
| Cipla | 1444.80 |
| Zydus Lifesciences | 1155.00 |
| Lupin | 2506.80 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: